Strategic Acquisition Following its acquisition by ANJAC Group in March 2022, Pillar5 Pharma may benefit from integrated distribution channels and expanded market reach, creating opportunities to introduce new pharmaceutical formulations and increase sales with existing and new partners.

Niche Manufacturing Capabilities Pillar5's unique ability to produce multi-dose preservative-free ophthalmic solutions and niche solid dose tablets and capsules positions it as a specialized contract manufacturer, offering tailored manufacturing services to pharmaceutical firms seeking high-compliance and quality formulations.

Quality Certifications With successful inspections by Health Canada and the FDA in 2013, Pillar5 demonstrates strong regulatory compliance, making it a reliable manufacturing partner for companies aiming to meet strict safety and quality standards in the North American healthcare market.

Market Focus and Growth Operating in the fast-growing pharmaceutical manufacturing sector with revenue between $25M and $50M, Pillar5 presents an attractive target for partnerships, licensing agreements, and contract manufacturing opportunities in both ophthalmic and solid-dose markets.

Robust Technical Foundation Leveraging advanced technology stack and a team with extensive formulation experience, Pillar5 can support innovation and custom development projects, making it an appealing collaborator for pharmaceutical companies seeking flexible, high-quality manufacturing solutions.